DNTH Bulls Dominate Positioning as Heavy Shorts Brace for the Print

Dianthus Therapeutics heads into tonight's earnings report with options traders at their most bullish in recent memory — while a large short base keeps the setup charged on both sides.

The options signal is the sharpest data point in the setup. The put/call ratio has dropped to 0.24, nearly four standard deviations below its 20-day average of 0.29 — a reading close to the 52-week low of 0.10, and the most call-heavy posture the options market has shown in months. That degree of skew reflects aggressive demand for upside exposure, not cautious hedging. It arrives as the stock has gained 17% over the past month to $110.40, adding another 4% on Tuesday alone and 8.7% across the week. Peers told a mixed story over the same stretch: STTK surged 16% on the week and XFOR added 9%, while SNDX and XENE each fell roughly 1–2%, suggesting DNTH's momentum has been selective rather than sector-wide.

Short interest complicates the picture. At 21% of free float — up roughly 27% over the past month — the short base is both large and growing, with official FINRA data putting days to cover near 8.9. That is a meaningful overhang heading into a binary catalyst. Yet the borrow market sends a contradictory signal: availability is ample at roughly 395%, meaning nearly four shares are available to borrow for every one already shorted, and cost to borrow has eased to around 0.5% — barely above negligible. Short sellers face no squeeze pressure in the lending market. The ORTEX short score of 67.4 has drifted lower from a peak near 71 three weeks ago, consistent with shorts trimming modestly as the stock climbed. The setup is therefore one of high conviction on both sides rather than a one-way crowded trade.

Analyst direction has been uniformly constructive. Evercore ISI raised its target to $134 just yesterday — the most recent bellwether move — while the broader consensus target of $128.58 implies around 16% upside from current levels. Raymond James upgraded to Strong Buy in March and Wolfe Research initiated at Outperform in April, giving the stock a wall of institutional endorsement. Bulls point to Claseprubart's potential across multiple autoimmune indications and a cash runway extended into 2030 following a recent offering. Bears counter that the pipeline is wholly dependent on a single lead candidate with no approved products and limited hard clinical data, and that tonight's update may expose gaps between elevated expectations and actual trial progress. FMR (Fidelity) holds 14.2% of shares — a position it grew by 1.3 million shares through June — while T. Rowe Price added 1.8 million shares over the same period, giving the stock a roster of institutions with meaningful skin in the game. On the insider side, the CFO sold roughly $3.1 million of stock in early July at prices around $100–102, about 10% below the current level — a modest caution flag heading into a print at a higher price.

The earnings report is therefore less a test of whether Dianthus can grow and more a test of whether tonight's clinical update on Claseprubart delivers data substantive enough to justify a stock that has tripled year-to-date and now carries 21% of its float sold short.